Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Company Overview More
Tengsheng Boyao Biotechnology Co., Ltd. is a biotechnology company headquartered in China and the United States, mainly engaged in infectious disease therapy research and development business. The company's products are used in infectious diseases (such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multidrug-resistant (MDR) or extensively drug-resistant (XDR) Gram-negative bacteria infections) and other diseases with significant public health burdens, such as central nervous system (CNS) diseases. The company also develops treatments for COVID-19 and others.
CEO: Zhi HONG
Market: Hong Kong motherboard
Futu Hot List
HKUSCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
02137 BRII-B
8.490+0.540+6.79%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Operating income
Operating expenses
Gross profit
Administrative expenses
-101.56% -208.4M -65.16% -67.99M -63.26% -103.4M -- -41.17M
Research and development expenses
43.52% -494.62M 40.69% -157.61M -945.29% -875.8M -- -265.74M
Revaluation surplus
-927.15% -3.6B -9833.13% -2.75B 12.75% -350.37M -- -27.7M
-Changes in the fair value of other assets
-927.15% -3.6B -9833.13% -2.75B 12.75% -350.37M -- -27.7M
Special items of operating profit
134.61% 111.96M -10.01% 24.49M 65.82% 47.72M -- 27.22M
Operating profit
-226.87% -4.19B -860.55% -2.95B -146.55% -1.28B -307.39M
Financing cost
29.56% -1.18M -7.07% -893K -49.87% -1.67M -- -834K
Earning before tax
-226.53% -4.19B -858.24% -2.95B -146.34% -1.28B -308.23M
After-tax profit from continuing operations
-226.53% -4.19B -858.24% -2.95B -146.34% -1.28B -308.23M
Earning after tax
-226.53% -4.19B -858.24% -2.95B -146.34% -1.28B -308.23M
Minority profit
71% -27.24M -40300% -402K -- -93.91M -- 1K
Profit attributable to shareholders
-250.02% -4.16B -858.11% -2.95B -128.32% -1.19B -308.23M
Basic earnings per share
-52.41% -9.48 -811.66% -14.86 -113.01% -6.22 -1.63
Diluted earnings per share
-52.41% -9.48 -811.66% -14.86 -113.01% -6.22 -1.63
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Deloitte Guan Huang Chen Fang Accountants--Deloitte Guan Huang Chen Fang Accountants--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Back to the Top